Abstract:Abstract Background Trypanosoma brucei is the causative agent for trypanosomiasis in humans and livestock, which presents a growing challenge due to drug resistance. While identifying novel drug targets is vital, the process is delayed due to a lack of functional information on many of the pathogen’s proteins. Accordingly, this paper presents a computational framework for prioritizing drug targets within the editosome, a vital molecular machinery responsible for mitochondrial RNA processing in T. brucei . Importantly, this framework may eliminate the need for prior gene or protein characterization, potentially accelerating drug discovery efforts. Results By integrating protein-protein interaction (PPI) network analysis, PPI structural modeling, and residue interaction network (RIN) analysis, we quantitatively ranked and identified top hub editosome proteins, their key interaction interfaces, and hotspot residues. Our findings were cross-validated and further prioritized by incorporating them into gene set analysis and differential expression analysis of existing quantitative proteomics data across various life stages of T. brucei . In doing so, we highlighted PPIs such as KREL2-KREPA1, RESC2-RESC1, RESC12A-RESC13, and RESC10-RESC6 as top candidates for further investigation. This includes examining their interfaces and hotspot residues, which could guide drug candidate selection and functional studies. Conclusion RNA editing offers promise for target-based drug discovery, particularly with proteins and interfaces that play central roles in the pathogen’s life cycle. This study introduces an integrative drug target identification workflow combining information from the PPI network, PPI 3D structure, and reside-level information of their interface which can be applicable to diverse pathogens. In the case of T. brucei , via this pipeline, the present study suggested potential drug targets with residue-resolution from RNA editing machinery. However, experimental validation is needed to fully realize its potential in advancing urgently needed antiparasitic drug development.

The proteasome as a target: How not tidying up can have toxic consequences for parasitic protozoa

Deciphering Host-Parasite Interplay in Leishmania Infection through a One Health View of Proteomics Studies on Drug Resistance

Discovery of Leishmania Druggable Serine Proteases by Activity-Based Protein Profiling

Targeting peptide based therapeutics: Integrated computational and experimental studies of autophagic regulation in host‐parasite interaction

An inhibitor targeting glycosome membrane biogenesis kills parasites

Development of subunit selective proteasome substrates for

Prioritization of Trypanosoma brucei editosome protein interactions interfaces at residue resolution through proteome-scale network analysis

Chemoproteomics: Towards Global Drug Target Profiling

The 26 S proteasome in Entamoeba histolytica: divergence of the substrate binding pockets from host proteasomes

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery

Parasites revive hope for cancer therapy

Exploring N-myristoyltransferase as a promising drug target against parasitic neglected tropical diseases

Structural analysis and shape-based identification of novel inhibitors targeting the Trypanosoma cruzi proteasome

Proteasome activation: A novel strategy for targeting undruggable intrinsically disordered proteins

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Treating cryptosporidiosis: A review on drug discovery strategies

High-Throughput Screening of Entamoeba Identifies Compounds Which Target Both Life Cycle Stages and Which Are Effective Against Metronidazole Resistant Parasites

Identification of novel anti‐leishmanials targeting glutathione synthetase of the parasite: a drug repurposing approach

Peptide-Alkoxyamine Drugs: An Innovative Approach to Fight Schistosomiasis: "Digging Their Graves with Their Forks"

Cover Feature: Chemoproteomics for Plasmodium Parasite Drug Target Discovery (ChemBioChem 16/2021)

Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome